IONIS PHARMACEUTICALS INC 4

Non-employee director Peter N. Reikes was awarded 3,399 Ionis Pharmaceuticals RSUs, convertible into common stock, as director compensation.

On July 15, 2026, Ionis Pharmaceuticals non-employee director Peter N. Reikes received a grant of 3,399 Restricted Stock Units (RSUs) under the company’s Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Each RSU represents a contingent right to receive one share of Ionis common stock or its cash equivalent. The award vests in three equal annual installments, beginning on July 15, 2027, with the RSUs fully vested by July 15, 2029; as of the grant date, none of the RSUs were vested. Following this grant, Reikes beneficially owns 3,399 shares (or share-equivalent RSUs) on a direct basis, and the filing reflects a routine equity compensation award rather than an open-market transaction.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

fda

Accession

0000874015-26-000247

Alert Tier

5